公开(公告)号：US20210363530A1

公开(公告)日：2021-11-25

申请号：US17387064

申请日：2021-07-28

申请人： CITY OF HOPE

发明人： John C. Burnett ,  Elizabeth Epps ,  John J. Rossi

IPC分类号： C12N15/113 ,  C12N15/86

摘要： Provided herein are, inter alia, oligonucleotides, kits, and methods useful for increasing lentiviral titers.

公开(公告)号：US11767530B2

公开(公告)日：2023-09-26

申请号：US17387064

申请日：2021-07-28

申请人： CITY OF HOPE

发明人： John C. Burnett ,  Elizabeth Epps ,  John J. Rossi

IPC分类号： C12N15/113 ,  C12N15/86

CPC分类号： C12N15/1132 ,  C12N15/86 ,  C12N2310/11 ,  C12N2310/33 ,  C12N2330/51 ,  C12N2740/16043 ,  C12N2740/16052

摘要： Provided herein are, inter alia, oligonucleotides, kits, and methods useful for increasing lentiviral titers.

公开(公告)号：US20230065784A1

公开(公告)日：2023-03-02

申请号：US17440832

申请日：2020-03-20

申请人： City of Hope

发明人： Saul J. Priceman ,  John C. Burnett ,  Yukiko Yamaguchi ,  Elizabeth Epps

IPC分类号： C07K14/725 ,  C07K16/28 ,  C12N15/63 ,  C12N15/113

摘要： Described herein is an approach for targeting multiple critical checkpoint genes involved in T cell exhaustion, for example, PD-1, TIM3, and LAG-3 in a manner that allows knock-down of their expression in T cells that also express a T cell receptor targeted to cancer cells, e.g., a CAR targeted to a cancer antigen or a T cell receptor (TCR).

公开(公告)号：US11104902B2

公开(公告)日：2021-08-31

申请号：US16648822

申请日：2018-09-21

申请人： CITY OF HOPE

发明人： John C. Burnett ,  Elizabeth Epps ,  John J. Rossi

IPC分类号： C12N15/113 ,  C12N15/86

摘要： MicroRNAs embedded within an intron, which are called ‘mirtrons,’ can be used as a platform for expressing one or more shRNA or miRNA mimics in a lentiviral vector. The inventors developed a strategy to improve lentiviral titering by reducing the production of shRNA/miRNA from the vector during packaging through the introduction of splice-inhibiting antisense oligonucleotides during vector packaging, which inhibit the splicing of the mirtron and subsequent processing of the shRNAs/miRNAs. In an aspect is provided a kit comprising an oligonucleotide comprising a mirtron splice site binding sequence and a lentiviral packaging system. In an aspect is provided a method for producing a lentivirus. The method comprises the step of transfecting a cell with an oligonucleotide comprising a mirtron splice site binding sequence and a lentiviral packaging system; thereby producing the lentivirus.

公开(公告)号：US20200216850A1

公开(公告)日：2020-07-09

申请号：US16648822

申请日：2018-09-21

申请人： CITY OF HOPE

发明人： John C. Burnett ,  Elizabeth Epps ,  John J. Rossi

IPC分类号： C12N15/113 ,  C12N15/86

摘要： MicroRNAs embedded within an intron, which are called ‘mirtrons,’ can be used as a platform for expressing one or more shRNA or miRNA mimics in a lentiviral vector. The inventors developed a strategy to improve lentiviral titering by reducing the production of shRNA/miRNA from the vector during packaging through the introduction of splice-inhibiting antisense oligonucleotides during vector packaging, which inhibit the splicing of the mirtron and subsequent processing of the shRNAs/miRNAs. In an aspect is provided a kit comprising an oligonucleotide comprising a mirtron splice site binding sequence and a lentiviral packaging system. In an aspect is provided a method for producing a lentivirus. The method comprises the step of transfecting a cell with an oligonucleotide comprising a mirtron splice site binding sequence and a lentiviral packaging system; thereby producing the lentivirus.